MetLife Investment Management
DNA icon

MetLife Investment Management’s Ginkgo Bioworks DNA Stock Holding History

MetLife Investment Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Buy
28,770
+5,822
+25% +$48.7K ﹤0.01% 2237
2026
Q1 		$141K Buy
22,948
+4,479
+24% +$37.3K ﹤0.01% 2383
2025
Q4 		$153K Sell
18,469
-5,778
-24% -$62.2K ﹤0.01% 2405
2025
Q3 		$354K Hold
24,247
– – ﹤0.01% 1989
2025
Q2 		$273K Buy
+24,247
New +$188K ﹤0.01% 2014
2024
Q2 		– Sell
-915
Closed -$42.5K – 2891
2024
Q1 		$42.5K Buy
915
+13
+1% +$673 ﹤0.01% 2729
2023
Q4 		$61K Sell
902
-5
-0.6% -$306 ﹤0.01% 2758
2023
Q3 		$65.6K Buy
907
+2
+0.2% +$160 ﹤0.01% 2784
2023
Q2 		$67.4K Buy
905
+287
+46% +$17K ﹤0.01% 2858
2023
Q1 		$32.9K Buy
618
+2
+0.3% +$127 ﹤0.01% 2748
2022
Q4 		$41.7K Buy
616
+22
+4% +$2.02K ﹤0.01% 2775
2022
Q3 		$74.1K Sell
594
-8
-1% -$953 ﹤0.01% 2731
2022
Q2 		$57.3K Buy
+602
New +$73.4K ﹤0.01% 2800

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Erste Asset Management
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

MetLife Investment Management's DNA Position: Q2 2026 in Review

MetLife Investment Management increased its Ginkgo Bioworks (DNA) stake by 25% in Q2 2026, buying an estimated $48.7K and bringing the position to 28,770 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #2237.

MetLife Investment Management first reported a position in DNA in Q2 2022 and has held it in 13 quarters since. The position peaked at $354K in Q3 2025. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • MetLife Investment Management held 28,770 shares of Ginkgo Bioworks worth $285K as of Q2 2026.
  • MetLife Investment Management bought 5,822 Ginkgo Bioworks shares in Q2 2026, an estimated $48.7K.
  • Ginkgo Bioworks made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2237 holding.
  • MetLife Investment Management first reported a position in Ginkgo Bioworks in Q2 2022 and has held it in 13 quarters since.
  • MetLife Investment Management's Ginkgo Bioworks position peaked at $354K in Q3 2025.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.